Teladoc Health - Livongo Transaction

IRS Form 8937

Livongo has determined that none of the special cash dividend equal to $7.09 per share paid to Livongo stockholders as of October 29, 2020 was paid out of its current or accumulated earnings and profits. Stockholders are urged to refer to the "U.S. Federal Income Tax Considerations" section of the definitive proxy statement contained in the registration statement filed by Teladoc on Form S-4 (File No. 333-248568) that was declared effective by the Securities and Exchange Commission on September 15, 2020, and to consult with their own tax advisors as to the tax consequences of the merger and the special dividend in their particular circumstances.

Get in touch today

Contact Teladoc Health Investor Relations

Michael Minchak | Vice President, Investor Relations |